RARE
Ultragenyx Pharmaceutical Inc.NASDAQHealthcare$22.45+1.87%ClosedMarket Cap: $2.17B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-28.56
P/S
3.29
EV/EBITDA
-6.36
DCF Value
$-492.36
FCF Yield
-21.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
83.8%
Operating Margin
-79.6%
Net Margin
-85.5%
ROE
-1024.4%
ROA
-37.6%
ROIC
-43.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $207.0M | 86.0% | $-114.0M | $-129.0M | $-1.29 | — |
| FY 2025 | $673.0M | 83.8% | $-535.0M | $-575.0M | $-5.83 | — |
| Q3 2025 | $159.9M | 82.5% | $-170.9M | $-180.4M | $-1.81 | — |
| Q2 2025 | $166.5M | 86.2% | $-107.9M | $-115.0M | $-1.17 | — |
| Q1 2025 | $139.3M | 79.4% | $-142.9M | $-151.1M | $-1.57 | — |
| Q4 2024 | $164.9M | 89.8% | $-122.3M | $-133.4M | $-1.39 | — |
| FY 2024 | $560.2M | 86.3% | $-536.0M | $-569.2M | $-6.29 | — |
| Q3 2024 | $139.5M | 84.9% | $-132.0M | $-133.5M | $-1.40 | — |
| Q2 2024 | $147.0M | 85.5% | $-116.4M | $-131.6M | $-1.52 | — |
| Q1 2024 | $108.8M | 83.9% | $-165.3M | $-170.7M | $-2.03 | — |
| Q4 2023 | $127.4M | 90.5% | $-122.0M | $-123.2M | $-1.52 | — |
| FY 2023 | $434.2M | 89.6% | $-569.2M | $-606.6M | $-8.25 | — |